F18.91
Inhalant use, unspecified, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Inhalant use disorder involves the problematic use of substances inhaled through the nose or mouth to achieve a mind-altering effect. When someone is in remission, it means they have stopped using inhalants and are not experiencing current symptoms of the disorder. The diagnosis coded as F18.91 indicates a history of inhalant use disorder that is now in remission, emphasizing that the individual is currently not engaging in problematic inhalant use, although they should continue to monitor their health and well-being.
Causes & Symptoms
Clinical Causes: Psychological factors such as stress, anxiety, depression, or peer pressure Environmental influences including exposure to environments where inhalants are accessible or normalized Underlying mental health conditions that may predispose to substance misuse Genetic predispositions that increase susceptibility to substance use disorders Lack of education or awareness about the risks associated with inhalant use Previous history of substance dependency or abuse
Key Symptoms: Previous inhalant use episodes characterized by euphoria, dizziness, or hallucinations Potential physical health issues resulting from past inhalant use, such as neurological or respiratory complications Cravings or urges related to inhalant use, especially during stressful times Emotional or psychological changes linked to past inhalant abuse Possible co-occurring mental health conditions like depression or anxiety No current signs of inhalant use, but risk factors for relapse may be present
Diagnostic & Treatment
Diagnosis Path: The diagnosis of inhalant use disorder in remission is made when an individual has a history of inhalant misuse that has stopped for a significant period, with no current symptoms or complications. Healthcare providers assess the patient's history, perform physical and mental health evaluations, and consider the duration of remission. This diagnosis emphasizes ongoing resilience and the importance of continued support to prevent relapse.
Treatment Protocols: While individuals in remission generally do not require acute treatment, ongoing support and monitoring are vital. Approaches include: - **Counseling and psychotherapy:** To address underlying psychological issues and develop coping strategies - **Support groups:** Participation in community or peer-led groups such as 12-step programs - **Lifestyle modifications:** Engaging in healthy activities, maintaining social connections, and avoiding triggers - **Addressing co-occurring conditions:** Managing other mental health concerns like anxiety or depression - **Regular follow-up:** Continued medical and psychological assessments to detect early signs of relapse and reinforce positive behaviors
Clinical Advice & FAQs
Billing Guidance
Is F18.91 a billable ICD-10 code?
Yes, F18.91 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F18.91?
Clinical documentation must specify the nature of Inhalant use, unspecified, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference